SEARCH

SEARCH BY CITATION

REFERENCES

  • Alami J, Williams BR, Yeger H. 2003. Derivation and characterization of a Wilms' tumour cell line, WiT 49. Int J Cancer 107: 365374.
  • Balciunas D, Wangensteen KJ, Wilber A, Bell J, Geurts A, Sivasubbu S, Wang X, Hackett PB, Largaespada DA, McIvor RS, Ekker SC. 2006. Harnessing a high cargo-capacity transposon for genetic applications in vertebrates. PLoS Genet 2: e169.
  • Bardeesy N, Falkoff D, Petruzzi MJ, Nowak N, Zabel B, Adam M, Aguiar MC, Grundy P, Shows T, Pelletier J. 1994. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 7: 9197.
  • Brown KW, Shaw AP, Poirier V, Tyler SJ, Berry PJ, Mott MG, Maitland NJ. 1989. Loss of chromosome 11p alleles in cultured cells derived from Wilms' tumours. Br J Cancer 60: 2529.
  • Canela A, Vera E, Klatt P, Blasco MA. 2007. High-throughput telomere length quantification by FISH and its application to human population studies. Proc Natl Acad Sci USA 104: 53005305.
  • Cawthon RM. 2002. Telomere measurement by quantitative PCR. Nucleic Acids Res 30: e47.
  • Faussillon M, Murakami I, Bichat M, Telvi L, Jeanpierre C, Nezelof C, Jaubert F, Gogusev J. 2008. Molecular cytogenetic anomalies and phenotype alterations in a newly established cell line from Wilms tumor with diffuse anaplasia. Cancer Genet Cytogenet 184: 2230.
  • Garvin AJ, Surrette F, Hintz DS, Rudisill MT, Sens MA, Sens DA. 1985. The in vitro growth and characterization of the skeletal muscle component of Wilms' tumor. Am J Pathol 121: 298310.
  • Garvin AJ, Sullivan JL, Bennett DD, Stanley WS, Inabnett T, Sens DA. 1987. The in vitro growth, heterotransplantation, and immunohistochemical characterization of the blastemal component of Wilms' tumor. Am J Pathol 129: 353363.
  • Garvin AJ, Re GG, Tarnowski BI, Hazen-Martin DJ, Sens DA. 1993. The G401 cell line, utilized for studies of chromosomal changes in Wilms' tumor, is derived from a rhabdoid tumor of the kidney. Am J Pathol 142: 375380.
  • Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. 1990. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 343: 774778.
  • Hazen-Martin DJ, Garvin AJ, Gansler T, Tarnowski BI, Sens DA. 1993. Morphology and growth characteristics of epithelial cells from classic Wilms' tumors. Am J Pathol 142: 893905.
  • Hazen-Martin DJ, Re GG, Garvin AJ, Sens DA. 1994. Distinctive properties of an anaplastic Wilms' tumor and its associated epithelial cell line. Am J Pathol 144: 10231034.
  • Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Zeidner J, Wu J, Liu T, Billups CA, Khan J, Ansher S, Zhang J, Smith MA. 2007. The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer 49: 928940.
  • Hu Q, Gao F, Tian W, Ruteshouser EC, Wang Y, Lazar A, Stewart J, Strong LC, Behringer RR, Huff V. 2011. Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation. J Clin Invest 121: 174183.
  • Huang CC, Gadd S, Breslow N, Cutcliffe C, Sredni ST, Helenowski IB, Dome JS, Grundy PE, Green DM, Fritsch MK, Perlman EJ. 2009. Predicting relapse in favorable histology Wilms tumor using gene expression analysis: A report from the Renal Tumor Committee of the Children's Oncology Group. Clin Cancer Res 15: 17701778.
  • Huff V. 1998. Wilms tumor genetics. Am J Med Genet 79: 260267.
  • Koesters R, Ridder R, Kopp-Schneider A, Betts D, Adams V, Niggli F, Briner J, von Knebel Doeberitz M. 1999. Mutational activation of the β-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res 59: 38803882.
  • Lobbert RW, Klemm G, Gruttner HP, Harms D, Winterpacht A, Zabel BU. 1998. Novel WT1 mutation, 11p LOH, and t(7;12) (p22;q22) chromosomal translocation identified in a Wilms' tumor case. Genes Chromosomes Cancer 21: 347350.
  • Lovvorn HN, Westrup J, Opperman S, Boyle S, Shi G, Anderson J, Perlman EJ, Perantoni AO, Wills M, de Caestecker M. 2007. CITED1 expression in Wilms' tumor and embryonic kidney. Neoplasia 9: 589600.
  • Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C, Biechele TL, Gingras AC, Zheng N, Maccoss MJ, Angers S, Moon RT. 2007. Wilms tumor suppressor WTX negatively regulates WNT/β-catenin signaling. Science 316: 10431046.
  • Muir TE, Cheville JC, Lager DJ. 2001. Metanephric adenoma, nephrogenic rests, and Wilms' tumor: A histologic and immunophenotypic comparison. Am J Surg Pathol 25: 12901296.
  • Robinson KM, Gregory MA, Nuss D, Kasvalu KM. 1980. Growth patterns, ultrastructure, and chromosomal constitution of normal kidney and nephroblastoma cells in short-term culture. J Pediatr Surg 15: 297302.
  • Roth J, Blaha I, Bitter-Suermann D, Heitz PU. 1988. Blastemal cells of nephroblastomatosis complex share an onco-developmental antigen with embryonic kidney and Wilms' tumor. An immunohistochemical study on polysialic acid distribution. Am J Pathol 133: 596608.
  • Rousseau MF, Nabarra B, Nezelof C. 1974. Behaviour of Wilms tumour and normal metanephros in organ culture. Eur J Cancer 10: 461466.
  • Royer-Pokora B, Busch M, Beier M, Duhme C, de Torres C, Mora J, Brandt A, Royer HD. 2010. Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm. Hum Mol Genet 19: 16511668.
  • Sens DA, Detrisac CJ, Sens MA, Rossi MR, Wenger SL, Todd JH. 1999. Tissue culture of human renal epithelial cells using a defined serum-free growth formulation. Exp Nephrol 7: 344352.
  • Smith MA, Morton CL, Phelps D, Girtman K, Neale G, Houghton PJ. 2008. SK-NEP-1 and Rh1 are Ewing family tumor lines. Pediatr Blood Cancer 50: 703706.
  • Stewart SA, Hahn WC, O'Connor BF, Banner EN, Lundberg AS, Modha P, Mizuno H, Brooks MW, Fleming M, Zimonjic DB, Popescu NC, Weinberg RA. 2002. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci USA 99: 1260612611.
  • Talts JF, Aufderheide E, Sorokin L, Ocklind G, Mattsson R, Ekblom P. 1993. Induction of mouse tenascin expression by a human sarcomatoid Wilms' tumor cell line growing in nude mice. Int J Cancer 54: 868874.
  • Venetsanakos E, Mirza A, Fanton C, Romanov SR, Tlsty T, McMahon M. 2002. Induction of tubulogenesis in telomerase-immortalized human microvascular endothelial cells by glioblastoma cells. Exp Cell Res 273: 2133.
  • Wegert J, Wittmann S, Leuschner I, Geissinger E, Graf N, Gessler M. 2009. WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact. Genes Chromosomes Cancer 48: 11021111.
  • Williams RD, Al-Saadi R, Chagtai T, Popov S, Messahel B, Sebire N, Gessler M, Wegert J, Graf N, Leuschner I, Hubank M, Jones C, Vujanic G, Pritchard-Jones K. 2010. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. Clin Cancer Res 16: 20362045.
  • Wittmann S, Zirn B, Alkassar M, Ambros P, Graf N, Gessler M. 2007. Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis. Genes Chromosomes Cancer 46: 163170.
  • Wittmann S, Wunder C, Zirn B, Furtwangler R, Wegert J, Graf N, Gessler M. 2008. New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors. Genes Chromosomes Cancer 47: 386395.
  • Zirn B, Samans B, Spangenberg C, Graf N, Eilers M, Gessler M. 2005a. All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo. Oncogene 24: 52465251.
  • Zirn B, Wittmann S, Graf N, Gessler M. 2005b. Chibby, a novel antagonist of the Wnt pathway, is not involved in Wilms tumor development. Cancer Lett 220: 115120.
  • Zirn B, Hartmann O, Samans B, Krause M, Wittmann S, Mertens F, Graf N, Eilers M, Gessler M. 2006. Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters. Int J Cancer 118: 19541962.